A Phase 2 interventional study of Cetrorelix in Endometriosis, sponsored by Solvay Pharmaceuticals. Completed at 57 sites in 8 countries. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2008-03-31.
Sponsored by Solvay Pharmaceuticals · Phase 2, Interventional, and Treatment
Identify effective doses of cetrorelix SR in the treatment of symptoms of endometriosis, describe dose effect relationship and duration of symptom relief
901 studies on the registry are indexed under Endometriosis; 259 are open to participants now.
Browse Endometriosis studies →Solvay Pharmaceuticals is the lead sponsor of 84 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
This study is completed, as verified in Mar 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Solvay Pharmaceuticals